BNP Paribas Financial Markets
MNPR icon

BNP Paribas Financial Markets’s Monopar Therapeutics MNPR Stock Holding History

BNP Paribas Financial Markets’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.6K Sell
741
-238
-24% -$14.7K ﹤0.01% 4733
2026
Q1 		$53.6K Sell
979
-36
-4% -$2.17K ﹤0.01% 4659
2025
Q4 		$66.3K Buy
1,015
+319
+46% +$26.1K ﹤0.01% 4560
2025
Q3 		$56.8K Buy
696
+349
+101% +$15.6K ﹤0.01% 4542
2025
Q2 		$12.4K Buy
+347
New +$12.6K ﹤0.01% 4795

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BNP Paribas Financial Markets's MNPR Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Monopar Therapeutics (MNPR) stake by 24% in Q2 2026, selling an estimated $14.7K and leaving 741 shares worth $68.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4733.

BNP Paribas Financial Markets first reported a position in MNPR in Q2 2025 and has held it in 5 quarters since. 85 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • BNP Paribas Financial Markets held 741 shares of Monopar Therapeutics worth $68.6K as of Q2 2026.
  • BNP Paribas Financial Markets sold 238 Monopar Therapeutics shares in Q2 2026, an estimated $14.7K.
  • Monopar Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4733 holding.
  • BNP Paribas Financial Markets first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 85 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.